Silverarc Capital Management, LLC Aligos Therapeutics, Inc. Transaction History

Silverarc Capital Management, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$0.64 - $1.13 $8,318 - $14,686	-12,997 Reduced 1.94%	655,515 $642,000
Q4 2023 Feb 14, 2024	BUY	$0.56 - $0.8 $20,510 - $29,300	36,625 Added 5.8%	668,512 $441,000
Q1 2023 May 15, 2023	BUY	$0.87 - $2.11 $549,741 - $1.33 Million	631,887 New	631,887 $549,000
Q2 2022 Jul 25, 2022	BUY	$1.04 - $2.14 $49,642 - $102,148	47,733 Added 447.82%	58,392 $71,000
Q1 2022 May 13, 2022	BUY	$2.08 - $12.2 $22,170 - $130,039	10,659 New	10,659 $23,000

227K

Ticker ALGS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,717,000
Market Cap $1.3B
Description
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB);...

Get notified when there are updates to the investment portfolio of Silverarc Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Silverarc Capital Management, LLC with notifications on news.